Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) Short Interest Up 71.6% in February

Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) saw a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 182,800 shares, an increase of 71.6% from the February 13th total of 106,500 shares. Based on an average trading volume of 2,260,000 shares, the short-interest ratio is currently 0.1 days. Approximately 2.2% of the shares of the stock are sold short.

Cyclacel Pharmaceuticals Price Performance

Shares of Cyclacel Pharmaceuticals stock opened at $0.30 on Friday. Cyclacel Pharmaceuticals has a 1 year low of $0.29 and a 1 year high of $4.00. The company has a market capitalization of $1.87 million, a P/E ratio of -0.03 and a beta of 0.28. The business has a 50 day moving average price of $0.35 and a 200 day moving average price of $0.58.

Analyst Ratings Changes

Separately, StockNews.com assumed coverage on Cyclacel Pharmaceuticals in a research report on Saturday. They set a “sell” rating for the company.

Insider Activity

In other news, CEO David E. Lazar sold 194,628,820 shares of Cyclacel Pharmaceuticals stock in a transaction that occurred on Wednesday, February 26th. The shares were sold at an average price of $0.03, for a total transaction of $5,838,864.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Insiders own 23.97% of the company’s stock.

Cyclacel Pharmaceuticals Company Profile

Cyclacel Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer and other proliferative diseases in the United States, the United Kingdom, and internationally. The company's lead product includes fadraciclib, a cyclin dependent kinase Inhibitors (CDK) that is in Phase 1/2 clinical trial for the treatment of solid tumors and hematological malignancies, as well as in combination with venetoclax to treat relapsed or refractory chronic lymphocytic leukemia; and Plogosertib, a polo-like kinase inhibitor program, which is in Phase 1/2 clinical trial for the treatment of advanced solid tumors and hematological malignancies.